FY2026 EPS Estimate for Tenet Healthcare Lifted by Analyst

Tenet Healthcare Corporation (NYSE:THC) – Equities researchers at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Tenet Healthcare in a report released on Thursday, August 13th. Zacks Research analyst Team now anticipates that the company will earn $20.32 per share for the year, up from their previous estimate of $17.52. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenet Healthcare’s current full-year earnings is $20.97 per share. Zacks Research also issued estimates for Tenet Healthcare’s Q4 2026 earnings at $5.04 EPS, Q2 2027 earnings at $4.66 EPS, Q3 2027 earnings at $4.50 EPS, Q4 2027 earnings at $5.13 EPS, FY2027 earnings at $18.91 EPS, Q2 2028 earnings at $5.35 EPS and FY2028 earnings at $20.09 EPS.

THC has been the topic of a number of other research reports. Truist Financial raised their price target on Tenet Healthcare from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Weiss Ratings downgraded Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 2nd. KeyCorp lowered their target price on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Guggenheim boosted their target price on Tenet Healthcare from $242.00 to $283.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. Finally, Barclays increased their price target on Tenet Healthcare from $240.00 to $271.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Tenet Healthcare currently has an average rating of “Moderate Buy” and an average target price of $273.00.

Tenet Healthcare Trading Up 2.3%

NYSE THC opened at $270.76 on Monday. The firm’s fifty day moving average is $214.32 and its two-hundred day moving average is $205.13. Tenet Healthcare has a one year low of $157.58 and a one year high of $271.92. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41. The firm has a market cap of $21.80 billion, a PE ratio of 10.44, a P/E/G ratio of 1.02 and a beta of 1.23.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, July 23rd. The company reported $6.12 EPS for the quarter, beating analysts’ consensus estimates of $4.26 by $1.86. The business had revenue of $6.04 billion for the quarter, compared to analysts’ expectations of $5.43 billion. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The company’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the company posted $4.02 EPS. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS.

Insider Buying and Selling at Tenet Healthcare

In related news, EVP Lisa Y. Foo sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $258.03, for a total value of $2,580,300.00. Following the sale, the executive vice president owned 32,053 shares in the company, valued at $8,270,635.59. This represents a 23.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Roy Blunt sold 600 shares of Tenet Healthcare stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $262.68, for a total value of $157,608.00. Following the transaction, the director directly owned 4,589 shares of the company’s stock, valued at approximately $1,205,438.52. This represents a 11.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 41,375 shares of company stock worth $9,793,347. Corporate insiders own 0.97% of the company’s stock.

Hedge Funds Weigh In On Tenet Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC increased its stake in shares of Tenet Healthcare by 6.1% during the 1st quarter. NewEdge Advisors LLC now owns 2,890 shares of the company’s stock worth $389,000 after purchasing an additional 166 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in Tenet Healthcare by 299.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,700 shares of the company’s stock valued at $229,000 after buying an additional 1,274 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in Tenet Healthcare during the second quarter worth $290,000. Quantbot Technologies LP acquired a new position in shares of Tenet Healthcare in the second quarter worth $65,000. Finally, Amundi lifted its position in shares of Tenet Healthcare by 4,207.8% in the second quarter. Amundi now owns 27,010 shares of the company’s stock valued at $4,652,000 after acquiring an additional 26,383 shares in the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.